

Siemens Nuclear Medicine Group

Siemens Medical Systems, Inc.
Nuclear Medicine Group
2501 North Barrington Road
Hoffman Estates, Illinois 60195-5203 U.S.A.
Telephone (708) 304-7700

We're Expanding our Horizon

With Infinite Possibilities



CAPINTEC IS ACCESSORIES!

Syringe Shields, Sharps Containers, Syringe Transports, Flood Sources, Survey Meters, Wipe Pads, Imaging Tables, Ventilation Products, and anything else needed to support your daily activities are available from Capintec. We're not just dose calibrators any more; we are expanding our horizon. With the same tradition of quality and service, you can now rely on Capintec for all your accessory needs.

Watch for our new expanded catalog with over 900 items for a complete one-stop shopping of all your needs.

CAPINTEC, INC.
6 Arrow Road, Ramsey, NJ USA 07446
Phone: (800) ASK-4-CRC or (201) 825-9500
Fax: (201) 825-4829

It's not over until you get past the artifacts

When female and large-chested or obese male patients undergo myocardial perfusion imaging, there is the potential for images to be peppered with artifacts—possibly resulting in inconclusive studies.

Cardiolite® comes through, especially in these patients. The higher photon energy (140 keV) provides greater anatomical detail to enhance interpretive confidence—which may reduce false-positives and equivocal cases.

Cardiolite also offers the unique advantage of direct measurement of both myocardial perfusion and ventricular function from one study.

So rather than settle for potentially inconclusive images, use Cardiolite and reduce soft-tissue attenuation.

Cardiolite®

Kit for the preparation of Technetium Tc99m Sestamibi

To reduce soft-tissue attenuation Cardiolite comes through

DU PONT
PHARMA
Radiopharmaceuticals

Stress testing should be performed only under the supervision of a qualified physician in a laboratory equipped with appropriate resuscitation and support apparatus. There have been infrequent reports of signs and symptoms consistent with seizure and severe hypersensitivity after administration of Tc99m Sestamibi.

Please see brief summary of prescribing information on adjacent page.

Brief Summary

Cardiolite®

Kit for the preparation of Technetium Tc99m Sestamibi

FOR DIAGNOSTIC USE

DESCRIPTION: Each 5ml vial contains a sterile, non-pyrogenic, lyophilized mixture of:
Tetrakis (2-methoxy isobutyl isonitrile) Copper (I) tetrafluoroborate - 1.0mg
Sodium Citrate Dihydrate - 2.6mg
L-Cysteine Hydrochloride Monohydrate - 1.0mg
Mannitol - 20mg
Stannous Chloride, Dihydrate, minimum ($SnCl_2 \cdot 2H_2O$) - 0.025mg
Stannous Chloride, Dihydrate, ($SnCl_2 \cdot 2H_2O$) - 0.075mg
Tin Chloride (Stannous and Stannic) Dihydrate, maximum (as $SnCl_2 \cdot 2H_2O$) - 0.086mg

Prior to lyophilization the pH is 5.3-5.9. The contents of the vial are lyophilized and stored under nitrogen.

This drug is administered by intravenous injection for diagnostic use after reconstitution with sterile, non-pyrogenic, oxidant-free Sodium Pertechnetate Tc99m Injection.The pH of the reconstituted product is 5.5 (5.0-6.0). No bacteriostatic preservative is present.

The precise structure of the technetium complex is $Tc99m[MIBI]_6^+$ where MIBI is 2-methoxy isobutyl isonitrile.

INDICATIONS AND USAGE: CARDIOLITE®, Kit for the Preparation of Technetium Tc99m Sestamibi is a myocardial perfusion agent that is useful in the evaluation of ischemic heart disease. CARDIOLITE®, Kit for the Preparation of Technetium Tc99m Sestamibi is useful in distinguishing normal from abnormal myocardium and in the localization of the abnormality, in patients with suspected myocardial infarction, ischemic heart disease or coronary artery disease. Evaluation of ischemic heart disease or coronary artery disease is accomplished using rest and stress techniques.

CARDIOLITE®, Kit for the Preparation of Technetium Tc99m Sestamibi is also useful in the evaluation of myocardial function using the first pass technique.

Rest-exercise imaging with Tc99m Sestamibi in conjunction with other diagnostic information may be used to evaluate ischemic heart disease and its localization.

In clinical trials, using a template consisting of the anterior wall, inferior-posterior wall and isolated apex, localization in the anterior or inferior-posterior wall in patients with suspected angina pectoris or coronary artery disease was shown. Disease localization isolated to the apex has not been established. Tc99m Sestamibi has not been studied or evaluated in other cardiac diseases.

It is usually not possible to differentiate recent from old myocardial infarction or to differentiate recent myocardial infarction from ischemia.

CONTRAINDICATIONS: None known.

WARNINGS: In studying patients in whom cardiac disease is known or suspected, care should be taken to assure continuous monitoring and treatment in accordance with safe, accepted clinical procedure. Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See Precautions).

PRECAUTIONS:

GENERAL

The contents of the vial are intended only for use in the preparation of Technetium Tc99m Sestamibi and are not to be administered directly to the patient without first undergoing the preparative procedure.

Radioactive drugs must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel. Also, care should be taken to minimize radiation exposure to the patients consistent with proper patient management.

Contents of the kit before preparation are not radioactive. However, after the Sodium Pertechnetate Tc99m Injection is added, adequate shielding of the final preparation must be maintained.

The components of the kit are sterile and non-pyrogenic. It is essential to follow directions carefully and to adhere to strict aseptic procedures during preparation.

Technetium Tc99m labeling reactions involved depend on maintaining the stannous ion in the reduced state. Hence, Sodium Pertechnetate Tc99m Injection containing oxidants should not be used.

Technetium Tc99m Sestamibi should not be used more than six hours after preparation.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.

Stress testing should be performed only under the supervision of a qualified physician and in a laboratory equipped with appropriate resuscitation and support apparatus.

The most frequent exercise stress test endpoints, which resulted in termination of the test during controlled Tc99m Sestamibi studies (two-thirds were cardiac patients) were:

Fatigue	35%
Dyspnea	17%
Chest Pain	16%
ST-depression	7%
Arrhythmia	1%

Carcinogenesis, Mutagenesis, Impairment of Fertility

In comparison with most other diagnostic technetium labeled radiopharmaceuticals, the radiation dose to the ovaries (1.5rads/30mCi at rest, 1.2 rads/30mCi at exercise) is high. Minimal exposure (ALARA) is necessary in women of childbearing capability. (See Dosimetry subsection in DOSAGE AND ADMINISTRATION section.)

The active intermediate, $[Cu(MIBI)_4]BF_4$, was evaluated for genotoxic potential in a battery of five tests. No genotoxic activity was observed in the Ames, CHO/HPRT and sister chromatid exchange tests (all *in vitro*). At cytotoxic concentrations (≥ 20μg/ml), an increase in cells with chromosome aberrations was observed in the *in vitro* human lymphocyte assay. $[Cu(MIBI)_4]BF_4$ did not show genotoxic effects in the *in vivo* mouse micronucleus test at a dose which caused systemic and bone marrow toxicity (9mg/kg, > 600 × maximal human dose).

Pregnancy Category C

Animal reproduction and teratogenicity studies have not been conducted with Technetium Tc99m Sestamibi. It is also not known whether Technetium Tc99m Sestamibi can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. There have been no studies in pregnant women. Technetium Tc99m Sestamibi should be given to a pregnant woman only if clearly needed.

Nursing Mothers

Technetium Tc99m Pertechnetate is excreted in human milk during lactation. It is not known whether Technetium Tc99m Sestamibi is excreted in human milk. Therefore, formula feedings should be substituted for breast feedings.

Pediatric Use

Safety and effectiveness in children below the age of 18 have not been established.

ADVERSE REACTIONS: During clinical trials, approximately 8% of patients experienced a transient parosmia and/or taste perversion (metallic or bitter taste) immediately after the injection of Technetium Tc99m Sestamibi. A few cases of transient headache, flushing, edema, injection site inflammation, dyspepsia, nausea, vomiting, pruritus, rash, urticaria, dry mouth, fever, dizziness, fatigue, dyspnea, and hypotension also have been attributed to administration of the agent. Cases of angina, chest pain, and death have occurred (see Warnings and Precautions). The following adverse reactions have been rarely reported: signs and symptoms consistent with seizure occurring shortly after administration of the agent; transient arthritis in a wrist joint; and severe hypersensitivity, which was characterized by dyspnea, hypotension, bradycardia, asthenia and vomiting within two hours after a second injection of Technetium Tc99m Sestamibi.

DOSAGE AND ADMINISTRATION: The suggested dose range for I.V. administration in a single dose to be employed in the average patient (70kg) is:

370-1110MBq (10-30mCi)

The dose administered should be the lowest required to provide an adequate study consistent with ALARA principles (see also PRECAUTIONS).

When used in the diagnosis of myocardial infarction, imaging should be completed within four hours after administration.

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to patient administration. Radiochemical purity should be checked prior to patient administration.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Store at 15-25°C before and after reconstitution.

RADIATION DOSIMETRY: The radiation doses to organs and tissues of an average patient (70kg) per 1110MBq (30mCi) of Technetium Tc99m Sestamibi injected intravenously are shown in Table 4.

Table 4. Radiation Absorbed Doses from Tc99m Sestamibi

	Estimated Radiation Absorbed Dose			
	REST			
	2.0 hour void		4.8 hour void	
Organ	rads/ 30mCi	mGy/ 1110MBq	rads/ 30mCi	mGy/ 1110MBq
Breasts	0.2	2.0	0.2	1.9
Gallbladder Wall	2.0	20.0	2.0	20.0
Small Intestine	3.0	30.0	3.0	30.0
Upper Large Intestine Wall	5.4	55.5	5.4	55.5
Lower Large Intestine Wall	3.9	40.0	4.2	41.1
Stomach Wall	0.6	6.1	0.6	5.8
Heart Wall	0.5	5.1	0.5	4.9
Kidneys	2.0	20.0	2.0	20.0
Liver	0.6	5.8	0.6	5.7
Lungs	0.3	2.8	0.3	2.7
Bone Surfaces	0.7	6.8	0.7	6.4
Thyroid	0.7	7.0	0.7	6.8
Ovaries	1.5	15.5	1.6	15.5
Testes	0.3	3.4	0.4	3.9
Red Marrow	0.5	5.1	0.5	5.0
Urinary Bladder Wall	2.0	20.0	4.2	41.1
Total Body	0.5	4.8	0.5	4.8
	STRESS			
	2.0 hour void		4.8 hour void	
Organ	rads/ 30mCi	mGy/ 1110MBq	rads/ 30mCi	mGy/ 1110MBq
Breasts	0.2	2.0	0.2	1.8
Gallbladder Wall	2.8	28.9	2.8	27.8
Small Intestine	2.4	24.4	2.4	24.4
Upper Large Intestine Wall	4.5	44.4	4.5	44.4
Lower Large Intestine Wall	3.3	32.2	3.3	32.2
Stomach Wall	0.5	5.3	0.5	5.2
Heart Wall	0.5	5.6	0.5	5.3
Kidneys	1.7	16.7	1.7	16.7
Liver	0.4	4.2	0.4	4.1
Lungs	0.3	2.6	0.2	2.4
Bone Surfaces	0.6	6.2	0.6	6.0
Thyroid	0.3	2.7	0.2	2.4
Ovaries	1.2	12.2	1.3	13.3
Testes	0.3	3.1	0.3	3.4
Red Marrow	0.5	4.6	0.5	4.4
Urinary Bladder Wall	1.5	15.5	3.0	30.0
Total Body	0.4	4.2	0.4	4.2

Radiopharmaceutical Internal Dose Information Center, July, 1990, Oak Ridge Associated Universities, P.O. Box 117, Oak Ridge, TN 37831, (615) 576-3449.

HOW SUPPLIED: Du Pont Radiopharmaceuticals' CARDIOLITE®, Kit for the Preparation of Technetium Tc99m Sestamibi is supplied as a 5ml vial in kits of two (2), five (5) and thirty (30) vials, sterile and non-pyrogenic.

Prior to lyophilization the pH is between 5.3-5.9. The contents of the vials are lyophilized and stored under nitrogen. Store at 15-25°C before and after reconstitution. Technetium Tc99m Sestamibi contains no preservatives. Included in each two (2) vial kit are one (1) package insert, six (6) vial shield labels and six (6) radiation warning labels. Included in each five (5) vial kit are one (1) package insert, six (6) vial shield labels and six (6) radiation warning labels. Included in each thirty (30) vial kit are one (1) package insert, thirty (30) vial shield labels and thirty (30) radiation warning labels.

The U.S. Nuclear Regulatory Commission has approved this reagent kit for distribution to persons licensed to use byproduct material pursuant to section 35.11 and section 35.200 of Title 10 CFR Part 35, to persons who hold an equivalent license issued by an Agreement State, and, outside the United States, to persons authorized by the appropriate authority.

DU PONT PHARMA
Radiopharmaceuticals

Marketed by
Du Pont Radiopharmaceutical Division
The Du Pont Merck Pharmaceutical Co.
331 Treble Cove Road
Billerica, Massachusetts, USA 01862

513121-0394
Brief Summary

3/94 Printed in U.S.A.

If you can only attend one medical conference in 1996,



ATTEND NUCLEAR MEDICINE'S FOREMOST INTERNATIONAL GATHERING

1996 promises to bring many exciting advances to the field of nuclear medicine. What better way to learn about the latest research and examine the newest technology than at the Society of Nuclear Medicine's 43rd Annual Meeting? Amidst the scenic beauty of Denver, the Mile High City, you can participate in the extensive scientific and educational programs, review posters, and visit with the numerous companies exhibiting nuclear medicine products and related services. In addition, you will have the opportunity to meet colleagues and other health care professionals from around the world.

Mark your calendars now for the Society of Nuclear Medicine's 43rd Annual Meeting in Denver, Colorado June 2 - 6, 1996

Please watch for the Meeting Preview Guide in early 1996

Maximal Vasodilation

for patients unable to exercise adequately



Imaging comparable to maximal exercise

- Interpretable images obtained in 98.7% of patients[1]
- Maximal coronary hyperemia achieved in 2-3 minutes
- No supplemental exercise necessary



Stress



Redistribution

Rapid onset, short duration

- <10-second half-life minimizes post-infusion monitoring time
- Side effects usually resolve quickly

ADENOSCAN®

adenosine

Please see brief summary of prescribing information on adjacent page for warnings, precautions and contraindications.

Fujisawa

1. Cerquiera MD, Verani MS, Schwaiger M, et al. Safety profile of adenosine stress perfusion imaging: results from Adenoscan multicenter trial registry. *J Am Coll Cardiol.* 1994;23:384-389.

BRIEF SUMMARY

ADENOSCAN®
adenosine

For Intravenous Infusion Only

DESCRIPTION

Adenosine is an endogenous nucleoside occurring in all cells of the body. It is chemically 6-amino-9-beta-D-ribofuranosyl-9-H-purine.

Adenosine is a white crystalline powder. It is soluble in water and practically insoluble in alcohol. Solubility increases by warming and lowering the pH of the solution.

Each Adenoscan vial contains a sterile, non-pyrogenic solution of adenosine 3 mg/mL and sodium chloride 9 mg/mL in Water for Injection, q.s. The pH of the solution is between 4.5 and 7.5.

INDICATIONS AND USAGE:

Intravenous Adenoscan is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. (See **WARNINGS**).

CONTRAINDICATIONS:

Intravenous Adenoscan (adenosine) should not be administered to individuals with:

1. Second- or third-degree AV block (except in patients with a functioning artificial pacemaker).
2. Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker).
3. Known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma).
4. Known hypersensitivity to adenosine.

WARNINGS:

Fatal Cardiac Arrest, Life Threatening Ventricular Arrhythmias, and Myocardial Infarction.

Fatal cardiac arrest, sustained ventricular tachycardia (requiring resuscitation), and nonfatal myocardial infarction have been reported coincident with Adenoscan infusion. Patients with unstable angina may be at greater risk.

Sinoatrial and Atrioventricular Nodal Block

Adenoscan (adenosine) exerts a direct depressant effect on the SA and AV nodes and has the potential to cause first-, second- or third-degree AV block, or sinus bradycardia. Approximately 6.3% of patients develop AV block with Adenoscan, including first-degree (2.9%), second-degree (2.6%) and third-degree (0.8%) heart block. All episodes of AV block have been asymptomatic, transient, and did not require intervention. Adenoscan can cause sinus bradycardia. Adenoscan should be used with caution in patients with pre-existing first-degree AV block or bundle branch block and should be avoided in patients with high-grade AV block or sinus node dysfunction (except in patients with a functioning artificial pacemaker). Adenoscan should be discontinued in any patient who develops persistent or symptomatic high-grade AV block. Sinus pause has been rarely observed with adenosine infusions.

Hypotension

Adenoscan (adenosine) is a potent peripheral vasodilator and can cause significant hypotension. Patients with an intact baroreceptor reflux mechanism are able to maintain blood pressure and tissue perfusion in response to Adenoscan by increasing heart rate and cardiac output. However, Adenoscan should be used with caution in patients with autonomic dysfunction, stenotic valvular heart disease, pericarditis or pericardial effusions, stenotic carotid artery disease with cerebrovascular insufficiency, or uncorrected hypovolemia, due to the risk of hypotensive complications in these patients. Adenoscan should be discontinued in any patient who develops persistent or symptomatic hypotension.

Hypertension

Increases in systolic and diastolic pressure have been observed (as great as 140 mm Hg systolic in one case) concomitant with Adenoscan infusion; most increases resolved spontaneously within several minutes, but in some cases, hypertension lasted for several hours.

Bronchoconstriction

Adenoscan (adenosine) is a respiratory stimulant (probably through activation of carotid body chemoreceptors) and intravenous administration in man has been shown to increase minute ventilation (Ve) and reduce arterial PCO_2 causing respiratory alkalosis. Approximately 26% of patients experience breathlessness (dyspnea) or an urge to breathe deeply with Adenoscan. These respiratory complaints are transient and only rarely require intervention.

Adenosine administered by inhalation has been reported to cause bronchoconstriction in asthmatic patients, presumably due to mast cell degranulation and histamine release. These effects have not been observed in normal subjects. Adenoscan has been administered to a limited number of patients with asthma and mild to moderate exacerbation of their symptoms has been reported. Respiratory compromise has occurred during adenosine infusion in patients with obstructive pulmonary disease. Adenoscan should be used with caution in patients with obstructive lung disease not associated with bronchoconstriction (e.g., emphysema, bronchitis, etc.) and should be avoided in patients with bronchoconstriction or bronchospasm (e.g., asthma). Adenoscan should be discontinued in any patient who develops severe respiratory difficulties.

PRECAUTIONS:

Drug Interactions

Intravenous Adenoscan (adenosine) has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, Adenoscan should be used with caution in the presence of these agents. The vasoactive effects of Adenoscan are inhibited by adenosine receptor antagonists, such as alkylxanthines (e.g., caffeine and theophylline). The safety and efficacy of Adenoscan in the presence of these agents has not been systematically evaluated. The vasoactive effects of Adenoscan are potentiated by nucleoside transport inhibitors, such as dipyridamole. The safety and efficacy of Adenoscan in the presence of dipyridamole has not been systematically evaluated. Whenever possible, drugs that might inhibit or augment the effects of adenosine should be withheld for at least five half-lives prior to the use of Adenoscan.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies in animals have not been performed to evaluate the carcinogenic potential of Adenoscan (adenosine). Adenosine was negative for genotoxic potential in the Salmonella (Ames Test) and Mammalian Microsome Assay.

Adenosine, however, like other nucleosides at millimolar concentrations present for several doubling times of cells in culture, is known to produce a variety of chromosomal alterations. In rats and mice, adenosine administered intraperitoneally once a day for five days at 50, 100, and 150 mg/kg [10-30 (rats) and 5-15 (mice) times human dosage on a mg/M^2 basis] caused decreased spermatogenesis and increased numbers of abnormal sperm, a reflection of the ability of adenosine to produce chromosomal damage.

Pregnancy Category C

Animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. Because it is not known whether Adenoscan can cause fetal harm when administered to pregnant women, Adenoscan should be used during pregnancy only if clearly needed.

Pediatric Use

The safety and effectiveness of Adenoscan in patients less than 18 years of age have not been established.

ADVERSE REACTIONS:

The following reactions with an incidence of at least 1% were reported with intravenous Adenoscan among 1421 patients enrolled in controlled and uncontrolled U.S. clinical trials. Despite the short half-life of adenosine, 10.6% of the side effects occurred not with the infusion of Adenoscan but several hours after the infusion terminated. Also, 8.4% of the side effects that began coincident with the infusion persisted for up to 24 hours after the infusion was complete. In many cases, it is not possible to know whether these late adverse events are the result of Adenoscan infusion.

Flushing	44%	Gastrointestinal discomfort	13%	Second-degree AV block	3%
Chest discomfort	40%	Lightheadedness/dizziness	12%	Paresthesia	2%
Dyspnea or urge to breathe deeply	28%	Upper extremity discomfort	4%	Hypotension	2%
Headache	18%	ST segment depression	3%	Nervousness	2%
Throat, neck or jaw discomfort	15%	First-degree AV block	3%	Arrhythmias	1%

Adverse experiences of any severity reported in less than 1% of patients include:

Body as a Whole: back discomfort; lower extremity discomfort; weakness.

Cardiovascular System: nonfatal myocardial infarction; life-threatening ventricular arrhythmia; third-degree AV block; bradycardia; palpitation; sinus exit block; sinus pause; sweating; T-wave changes, hypertension (systolic blood pressure > 200 mm Hg).

Central Nervous System: drowsiness; emotional instability; tremors.

Genital/Urinary System: vaginal pressure; urgency.

Respiratory System: cough.

Special Senses: blurred vision; dry mouth; ear discomfort; metallic taste; nasal congestion; scotomas; tongue discomfort.

OVERDOSAGE:

The half-life of Adenosine is less than 10 seconds and side effects of Adenoscan (when they occur) usually resolve quickly when the infusion is discontinued, although delayed or persistent effects have been observed. Methylxanthines, such as caffeine and theophylline, are competitive adenosine receptor antagonists and theophylline has been used to effectively terminate persistent side effects. In controlled U.S. clinical trials, theophylline (50-125 mg slow intravenous injection) was needed to abort Adenoscan side effects in less than 2% of patients.

DOSAGE AND ADMINISTRATION:

For intravenous infusion only.

Adenoscan should be given as a continuous peripheral intravenous infusion.

The recommended intravenous dose for adults is 140 mcg/kg/min infused for six minutes (total dose of 0.84 mg/kg).

The required dose of thallium-201 should be injected at the midpoint of the Adenoscan infusion (i.e., after the first three minutes of Adenoscan). Thallium-201 is physically compatible with Adenoscan and may be injected directly into the Adenoscan infusion set.

The injection should be as close to the venous access as possible to prevent an inadvertent increase in the dose of Adenoscan (the contents of the IV tubing) being administered. There are no data on the safety or efficacy of alternative Adenoscan infusion protocols.

The safety and efficacy of Adenoscan administered by the intracoronary route have not been established.

Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

CAUTION: Federal law prohibits dispensing without prescription.

Fujisawa USA, Inc.
Deerfield, IL 60015
Under license from Medco Research, Inc.
Research Triangle Park, NC 27709

BIAD XLT with 90° Detector & Coincidence Mode Options

Phantom Test Image



from BIAD in
Coincidence Mode



180° Body SPECT

Close Proximity
90° Cardiac SPECT

The Best SPECT Images in Nuclear Medicine
- Perfect multi-detector COR alignment
- Patented X-Y shift correction
- Isotope-specific linearity and flood corrections
- SESAME Scatter Elimination
- ACTION nonuniform Attenuation Correction
- DSF Resolution Recovery
- FDG/MIBI Dual Isotope Simultaneous Acquisition
- Gated SPECT / 3D LVEF
- Fan beam Brain SPECT
- WholeBody SPECT
- Coincidence mode tomo imaging

Imaging Your Complete Patient Population
- Industry-best 500 lb. patient weight capacity
- Industry-best 36" gantry opening
- Whisper-Quiet Operation

The Most Efficient Clinical SPECT Imaging
- QuickVIEW integrated p-scope and system display
- Automated pre-scan system set-up
- Simple and flexible protocol-based scan setup
- DICOM 3.0/ Interfile
- Image Co-Registration/ Fusion
- SUN workstation featuring X/Open CDE

TRIONIX

8037 Bavaria Road •Twinsburg, Ohio 44087 USA • Telephone: (216) 425-9055 •Fax: (216) 425-9059 • Dec. 1995

510K Pending

SESAME + ACTION + DSF Recovery

Benefits of Transmission Attenuation Correction & DSF Resolution Recovery



A. Conv. **B.** Bkg. Subtr. **C.** ACTION + DSF

A. Conventional filtered back-projection
B. Conventional dc background subtraction.
C. Attenuation Correction by Transmission Information Observation Network method. DSF means Detector Spread Function Resolution Recovery

Benefits of Scatter Elimination, Transmission Attenuation Correction & DSF Resolution Recovery



A. Conv. **B.** SESAME **C.** SESAME+ ACTION+DSF

A. Conventional filtered back-projection
B. SESAME is Scatter Elimination by Spectral Acquisition Memory Extension
C. Attenuation Correction by Transmission Information Observation Network method. DSF means Detector Spread Function Resolution Recovery

TRIONIX

8037 Bavaria Road •Twinsburg, Ohio 44087 USA • Telephone: (216) 425-9055 •Fax: (216) 425-9059 • Dec. 1995

THE SOURCE FOR RADIOISOTOPE SHIELDING AND STORAGE

Biodex Medical Systems offers a wide range of Radioisotope shielding and handling products all designed specifically to meet the demanding needs of the Nuclear Medicine professional.

A Full array of Syringe Shields including the Pro-Tec® II, the Pro-Tec III and the NEW Pro-Tec IV - "Full View" Lead Glass Syringe Shield

new • **Pro-Tec IV "Full View" Syringe Shield** *This new syringe shield features 360° viewing through high density 6.2 leaded glass with tip-to-tip visibility.*

• **Pro-Tec III** *The all new Syringe Shield featuring a unique Safe-T-Lock design that immediately grips and secures the syringe in place and releases it by the simple press of a button.*

• **Pro-Tec β** *For administering Strontium 89, P-32 and other Beta emitting radiopharmaceuticals. Unique construction completely attenuates Beta emissions and errant Bremsstrahlung*

Other syringe shields and accessories include:

- **Dose Drawing Syringe Shield**
- **Thallium Injection Shield**
- **Color Coded Lead Glass and Lead Acrylic Syringe Shields**
- **New Syringe Shield Holder**
- **Color Coded and Standard Vial Shields**
- **Tungsten and lead Glass Vial Shields** *and more...*

BIODEX MEDICAL

LEAD LINED Shielding and Storage Products is unmatched for quality and design. *A full assortment of modular furniture, affording the technologist the right module for the job. Whether custom designed or standard, Biodex can meet your most demanding specifications.*

new • **Radioisotope Storage Modules** *New Unit Dose Module stores unit ammo boxes, rotates three sharps containers, holds flood sources, phantoms, and small containers requiring lead shielding.*

• **Preparation Enclosure** *This counter mounted fume hood connects to external ductwork and and is completely shielded with 1/4" lead, encased in stainless steel.*

new • **Lead Lined Waste Container** *a must for any facility that generates radioactive waste. Constructed entirely of stainless steel, the container's special design protects the user even when the hatch is open.*

• **Table Top Lead Shielded Barriers** *come in mini or standard size - both offer full upper torso protection, built-in stainless steel work tray and the option of bottomshielding.*

• **Lead Lined Sharps Shields** *safely contains "HOT", used syringes prior to final disposal. Choose either a single or the NEW Dual Container model .*

• **Lead Shielded Syringe Holders** *either single or multiple styles to choose from.*

new *Lead Lined Unit Dose Module*



new *Full-View Pro-Tec IV*

Table Top Shielded Barriers



new *Lead Lined Waste Container*

Radioisotope Modular Furniture

CALL 1-800-224-6339 FOR A

N:95-078 5/95

THE ATOMLAB™ FAMILY OF NUCLEAR PRODUCTS

THE ATOMLAB™ 100 DOSE CALIBRATOR

- All functions are microprocessor controlled
- Ultra-fast response
- Automatic range selection
- Automatic background subtraction and zeroing
- Remote ionization chamber with 10-foot cable
- Self-diagnostic software
- Daily constancy isotope keys
- Electronic power supply (no battery in chamber)
- Industry exclusive 2-year warranty
- UL listed

The Atomlab™ 100 uses specially designed software and microprocessor technology to provide fast, accurate activity measurements with performance that easily surpasses the latest most, stringent regulatory requirements.

THE ATOMLAB™ 100^{plus} DOSE CALIBRATOR

- All the feature of the Atomlab™ 100 as well as:
- Clock/Calendar
- Prints "peel & stick" syringe / report labels
- 3 daily constancy isotope keys
- Prints constancy reports with carbonless copies for Co-57, Cs-137, and Ba-133
- Saves up to 2 months of constancy data.
- Sr-89 now pre-defined
- RS-232 serial port standard

The new Atomlab 100^{plus} performs all standard dose calibration and then some. With more features than the Atomlab100 at less cost than the Atomlab 200 - Atomlab100^{plus} is a great investment.

THE ATOMLAB™ 200 DOSE CALIBRATOR

- Inventory control of 25 samples, correcting for volume,activity and moly concentration
- Volume determination and future dose computations
- Pharmaceutical purity quality control
- Isotope decay protection
- Automatic linearity calculations using attenuator tubes
- All enhanced functions performed with push button control
- Advanced dot matrix printer

THE ATOMLAB™ 300 DOSE CALIBRATOR

- Extended measurement range
- Ultra-fast response time
- Factory calibrated for all PET isotopes

The Atomlab 300 PET Dose Calibrator is designed specifically to meet the needs of Positron Emission Tomography. It's ultra-fast response time,extended measurement range and computer compatibility provide state of the art performance for both clinical as well as research PET.

THE ATOMLAB™ 450 WIPE TEST SYSTEM

- Complete wipe test system including Schilling, red cell survival, blood volume.
- Macintosh based
- Easy to use
- 1024 Channel MCA
- Isotope discrimination, identification and spectral analysis.

THE ATOMLAB™ 950 THYROID UPTAKE SYSTEM

- The only POWER MAC based Thyroid Uptake System
- Easy to learn, easy to use
- 1024 Channel Multi-Channel Analyzer
- Real-time patient data
- In-Vitro programs for RBC Survival and Blood Volume
- ***NEW*** Hematology Mode includes programs for GFR and ERPF
- Extensive Wipe Test program
- Compatible with any MacIntosh software program

The new Atomlab 950 Uptake System combines the speed, sophistication and ease of use of a Power Mac with the creative programming of Biodex to produce the first Mac-based Thyroid Uptake System. Just turn it on and go.

THE ATOMLAB™ 930 THYROID UPTAKE SYSTEM

- Fast, accurate reproducible results
- Auto-calculation and calibration
- Complements any size nuclear medicine department
- Uptakes, Bioassay, Wipe Testing, Schilling, Manual MCA mode and more....

The Atomlab 930 is a complete Thyroid Uptake System specifically designed for nuclear medicine professionals, capable of performing a wide array of functions including Updates, Bioassay, Wipe Test, Schilling, Manual MCA mode.

BIODEX MEDICAL

FREE 150 PAGE BIODEX CATALOG

Brookhaven R&D Plaza • 20 Ramsay Road • Box 702 • Shirley • New York • 11967-0702 • 516-924-9000 • Fax 516-924-9241

Defining the Field . . .
New Titles in Technology from the Society of Nuclear Medicine

Recently published books from SNM provide authoritative, up-to-date discussion of key subjects in nuclear medicine technology. Adding to your professional library has never been easier—Simply call the toll-free number below for fast, efficient service.



CLINICAL COMPUTERS IN NUCLEAR MEDICINE
Katherine L. Rowell, MS, CNMT, Editor

$35 members/$49 non-members. A companion text to *Computers in Nuclear Medicine,* this survey traces the evolution of nuclear medicine computer technology.
An essential guide for staff operating computers in clinical settings.

COMPUTERS IN NUCLEAR MEDICINE: A PRACTICAL APPROACH
Kai Lee, PhD

$30 members/$42 non-members.This illustrated guide explains both how computers work and how processing techniques obtain diagnostic information from radionuclide images.

A PATIENT'S GUIDE TO NUCLEAR MEDICINE, REVISED EDITION

Pamphlet, $0.40 (100 copies, minimum order). This popular pamphlet explains nuclear medicine procedures in clear, concise language, helping to allay patient anxieties. Format includes common questions and answers; step-by-step descriptions of procedures; photographs showing patients undergoing imaging. An update of the highly successful patient pamphlet in use since 1983.



REVIEW OF NUCLEAR MEDICINE TECHNOLOGY
Ann M. Steves, MS, CNMT

$30 members/$42 non-members.Both an overview of the latest techniques in nuclear medicine technology as well as an authoritative study guide, this practical handbook is a valuable addition to the libraries of students and specialists alike.



CURRICULUM GUIDE FOR NUCLEAR MEDICINE TECHNOLOGISTS, 2ND EDITION,
Wanda M. Mundy, EdD, CNMT and Gregory Passmore, MS, CNMT

$13.95 (Ask about special student pricing.). An invaluable tool for educators and program administrators, this new edition of the *Curriculum Guide* also serves continuing education aims for those already working in the field.Thoroughly revised in response to latest advances in nuclear medicine technology.

TO ORDER, CALL TOLL-FREE, Matthews Medical Books, 1-800-633-2665 (Outside the U.S. 314-432-1401)

AccuSync™

DIAGNOSTIC MEDICAL INSTRUMENTS

The Finest Line of Cardiac Gates Available



For over fourteen years, Advanced Medical Research, now known as AccuSync Inc., has been serving the cardiac health care industry with the finest line of cardiac gates available in today's market.

Our dedication to service and commitment to provide you with a reliable product have built the reputation of our gates.

With a complete line of models available, you are able to choose the gate which best corresponds to your specific requirements.

The AccuSync 5L, our top model (featured at left) includes CRT monitor (visual) and Strip Chart Recorder (hard copy).

Model Specifications:

- Auto/Manual trigger control
- No delay
- ECG output
- Audio indicator
- Trigger pulse LED
- Isolation amplifier for patient safety
- Compatible with all computers

AccuSync models 5L, 6L and 1L are CSA and ETL (UL544) approved



Model	Strip Chart	CRT Monitor	HR/R-R Int	Trigger
5L	•	•	•	•
6L		•	•	•
1L	•		•	•
3L			•	•
4M				•

Accessory and optional products available:
The AccuAmp 5, the 5 lead system available for AccuSync 5L, 6L, and 1L, transmits information through fiber optic link. Patient cables, lead wires, and BNC cables available for AccuSync models.

AccuSync INC.
132 Research Drive • Milford CT 06460
Phone (203) 877-1610 • Fax (203)877-8972

AccuSync Inc. formerly known as Advanced Medical Research Corporation

Circle Reader Service No. 7

Position Available

Dual Qualified Radiology/Nuclear Medicine Specialist, British Columbia

Madrona X-Ray, in conjunction with Nanaimo Regional General Hospital, is seeking applicants for combined hospital/private practice with a group of six progressive radiologists. The successful applicant would be the first nuclear medicine physician for a small new nuclear medicine facility at a 411 bed regional hospital with local population of 120,000 and a draw area for nuclear medicine of 250,000. Departmental services include CT, angiography, ultrasound, echocardiography, diagnostic and screening mammography and non-vascular interventional radiology. Applicants must be eligible for BC billing numbers and BC College licensure and meet hospital accreditation requirements. Please reply with curriculum-vitae and cover letter to: Dr. R. Bissonnette, Director of Medical Imaging, Nanaimo Regional General Hospital, 1200 Dufferin Crescent, Nanaimo, BC., V9S 2B7. Fax: (604) 755-7652, Telephone: (604) 755-7608.

General Radiology/Nuclear Medicine

The Department of Diagnostic Radiology at Yale University School of Medicine seeks a senior level nuclear medicine physician with experience and expertise in general radiology as well. Responsibilities will include: nuclear medicine and general radiology coverage at the Universityís two teaching hospitals as well as at satellite outpatient facilities. Documented interest and ability in teaching and in clinical research are essential. The individual will be responsible for assuming a major role in clinical research and mentoring of junior faculty. A major function of this position will be the development of satellite radiologic facilities. Management and administrative experience in a private practice setting will be a valuable asset to any applicants for this position. Please send a letter of interest and a CV to: Dr. Bruce L. McClennan, Chairman, Department of Diagnostic Radiology, Yale University School of Medicine, P.O. Box 208042, New Haven, CT 06520-8042. EOE/AA. Application deadline: March 15, 1996.

Manager, Nuclear Medicine

The George Washington University Medical Center has a career opportunity for a Manager, Nuclear Medicine to supervise staff and direct clinical operations of a busy nuclear medicine division. To qualify you must possess NMTCB or ARRT certification, and a min. of 3 years of supervisory experience. BS degree preferred. We offer a comprehensive compensation package to include health insurance and tuition benefits. To ensure consideration, reference Reg. #1472 and mail or fax a resume to: EC, Reg. #1472, Medical Center Recruitment, The George Washington University, 2150 Penn. Ave., N.W., Suite 1-411, Washington, D.C. 20037. Fax: (202) 994-9783 Fax. GW is an equal opportunity employer.

Nuclear Medicine ABR Special Competency or ABNM Residency Position

Unexpected opening for 1 year ABR special competency or 2 year nuclear medicine residency to begin July 1996. Program involves 3 hospitals with diverse patient population and state-of-the-art PACS, teleradiology and SPECT imaging equipment. Strong emphasis on teaching and research. The University is located at the base of the beautiful Wasatch Mountains with skiing, hiking and other outdoor activities nearby. If interested contact: Frederick L. Datz, MD, at the University of Utah Health Sciences Center (801) 581-2369.

Nuclear Pharmacist

Cox Nuclear Pharmacies needs pharmacy managers and staff pharmacists for positions available in one of several locations in Birmingham, AL, Mobile, AL, Panama City, FL or Biloxi, MS. Please call Billy Cox or Elaine Hyatt M-F at 1-800-269-6825.

PET Fellowship

PET fellowship available at West Los Angeles Veterans Affairs Medical Center. Begins July 1, 1996. PET facility has a new Siemens 953/31 tomograph and on-site cyclotron for FDG, N-13 and O-15 production. Stipend is PGY-4 level full-time for 6 months or half-time for 12 months. Call Dr. William H. Blahd, (310) 268-3587.

Postdoctoral Fellowship in PET/SPECT/fMRI Imaging

Unique opportunity for postdoctoral training in functional brain imaging research. Emphasis on psychopharmacology and neuropsychiatric imaging. Special training in qualification techniques, research methods and clinical applications. Didactic lectures, variety of projects, excellent mix of clinical and basic research. MD or Md/PhD and clinical credentials required. Position to start immediately. Send applications to: Dean F. Wong, MD, PhD, Johns Hopkins Medical Institutions, Radiology-JHOC Bldg. Room 3245, 601 N. Caroline Street, Baltimore, MD 21287-0807. E-mail: dfwong@rad.jhu.edu.

Position Wanted

Experienced ABNM certified physician seeks FT job. Dr. Garcia: (914) 778-2601.

ABNM certified physician seeks FT/PT position. Available July 1996 or earlier. Please respond to the Society of Nuclear Medicine, Box #201, 1850 Samuel Morse Dr., Reston, VA 22090-5316.

ADAC
ADAC LABORATORIES

Clinical Development Grants
in
NUCLEAR MEDICINE

ADAC Laboratories announces the continuing support of development grants to Clinical Nuclear Medicine. Previously, grants were awarded to

94/95	95/96
University of South Florida,Tampa	Northwestern University, Chicago
University of California, San Francisco	Cedars Sinai, Los Angeles
Denver Medical Imaging, Denver	Emory University, Atlanta
University New York, Stonybrook	Notre Dame Hospital, Canada
University of Leuven, Belgium	
AVL Cancer Institute, Holland	
University of Dresden, Germany	

Several grants ranging from $5000 to $50,000 will be awarded for 1996/97. Funds can be used for equipment and personnel support for a 12 month project.

Preferences will be given to high energy imaging as it relates to effectiveness of nuclear medicine procedures for diagnostic efficacy and payor reimbursement.

Applications will be reviewed by an independent review committee of nuclear medicine professionals.

For application forms and information please write to:
Advanced Clinical Research Program
ADAC Laboratories
540 Alder Drive
Milpitas, CA 95035

Application Deadline: March 31, 1996

Funding Announcements: SNM - 1996

Funding Available: January 31,1997

Leadership • Technology
BETTER HEALTH CARE
Circle Reader Service No. 1

VariCam



Get an angle on the future...

All-Digital, High-Energy Imaging

- ❑ Designed for coincidence detection (work-in-progress)
- ❑ Leading in High-Energy Imaging
- ❑ TransACT™: Transmission Attenuation Corrected Tomography



Robotic Design, Convertible Geometry

- ❑ EleGantry™: Truly open, variable-angle (180°/90°) detector geometry
- ❑ OptiTrack™: Real-time fully automatic body-contoured scanning
- ❑ Evolving-Images™ with Slip-Ring technology

*SPECT studies performed by gamma cameras using positron emitting isotopes (511 keV) are not cleared by the FDA. Images presented demonstrate clinical results obtained in investigational studies.



Double-efficiency
Whole-Body scan, featuring superior lesion detectability with OptiTrack real-time body contouring.



Double-efficiency
*right-angle cardiac tomography: simultaneous dual-isotope FDG/MIBI SPECT.**



Double double-efficiency
ultra-flared fan-beam NeuroScintigraphy.

Elscint

Circle Reader Service No. 42

Elscint U.S.A.: (201) 342-2020; 1-800-ELSCINT